305 related articles for article (PubMed ID: 18541380)
1. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
Palmer JA; Higuera ES; Chang L; Chaplan SR
Neuroscience; 2008 Jul; 154(4):1554-61. PubMed ID: 18541380
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
Chang L; Luo L; Palmer JA; Sutton S; Wilson SJ; Barbier AJ; Breitenbucher JG; Chaplan SR; Webb M
Br J Pharmacol; 2006 May; 148(1):102-13. PubMed ID: 16501580
[TBL] [Abstract][Full Text] [Related]
3. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
5. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
6. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
7. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
[TBL] [Abstract][Full Text] [Related]
8. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Wise LE; Shelton CC; Cravatt BF; Martin BR; Lichtman AH
Eur J Pharmacol; 2007 Feb; 557(1):44-8. PubMed ID: 17217945
[TBL] [Abstract][Full Text] [Related]
9. FAAH and anandamide: is 2-AG really the odd one out?
Di Marzo V; Maccarrone M
Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
[TBL] [Abstract][Full Text] [Related]
10. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol.
Ho WS; Randall MD
Br J Pharmacol; 2007 Mar; 150(5):641-51. PubMed ID: 17245358
[TBL] [Abstract][Full Text] [Related]
11. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB
Leonard MZ; Alapafuja SO; Ji L; Shukla VG; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
J Pharmacol Exp Ther; 2017 Dec; 363(3):314-323. PubMed ID: 28947487
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
14. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
Caprioli A; Coccurello R; Rapino C; Di Serio S; Di Tommaso M; Vertechy M; Vacca V; Battista N; Pavone F; Maccarrone M; Borsini F
J Pharmacol Exp Ther; 2012 Jul; 342(1):188-95. PubMed ID: 22514334
[TBL] [Abstract][Full Text] [Related]
15. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.
Schlosburg JE; Kinsey SG; Lichtman AH
AAPS J; 2009 Mar; 11(1):39-44. PubMed ID: 19184452
[TBL] [Abstract][Full Text] [Related]
16. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.
Maione S; De Petrocellis L; de Novellis V; Moriello AS; Petrosino S; Palazzo E; Rossi FS; Woodward DF; Di Marzo V
Br J Pharmacol; 2007 Mar; 150(6):766-81. PubMed ID: 17279090
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.
Holt S; Paylor B; Boldrup L; Alajakku K; Vandevoorde S; Sundström A; Cocco MT; Onnis V; Fowler CJ
Eur J Pharmacol; 2007 Jun; 565(1-3):26-36. PubMed ID: 17397826
[TBL] [Abstract][Full Text] [Related]
18. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
19. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
Hillard CJ
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):3-18. PubMed ID: 10785538
[TBL] [Abstract][Full Text] [Related]
20. Anandamide hydrolysis: a new target for anti-anxiety drugs?
Gaetani S; Cuomo V; Piomelli D
Trends Mol Med; 2003 Nov; 9(11):474-8. PubMed ID: 14604824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
